بدائل البحث:
significant cause » significant change (توسيع البحث), significant changes (توسيع البحث), significant gap (توسيع البحث)
significant base » significant based (توسيع البحث), significant bias (توسيع البحث), significance based (توسيع البحث)
cause decrease » caused decreased (توسيع البحث), use decreased (توسيع البحث), causes increased (توسيع البحث)
base case » use case (توسيع البحث)
significant cause » significant change (توسيع البحث), significant changes (توسيع البحث), significant gap (توسيع البحث)
significant base » significant based (توسيع البحث), significant bias (توسيع البحث), significance based (توسيع البحث)
cause decrease » caused decreased (توسيع البحث), use decreased (توسيع البحث), causes increased (توسيع البحث)
base case » use case (توسيع البحث)
-
21
-
22
-
23
The base case analysis.
منشور في 2025"…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …"
-
24
Base-case results.
منشور في 2025"…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …"
-
25
Base-case results.
منشور في 2024"…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …"
-
26
Base-case analysis.
منشور في 2023"…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …"
-
27
-
28
Deterministic result of the base-case analysis.
منشور في 2024"…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …"
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
Capsaicin, pyridoxine, vincristine sulfate and ionomycin significantly decreased axon length ratio but only pyridoxine had no impact on neurotoxicity.
منشور في 2024"…(<b>C</b>) Pyr at 500 μM significantly decreased axon length ratio over time and was significantly lower than PBS control by day 3. …"
-
37
-
38
Concentrations of particles that caused significant decreases in the viability of SNU-1 cells compared to untreated cells during 1, 2, 4, 6 or 24 h treatment periods.
منشور في 2021"…<p>Concentrations of particles that caused significant decreases in the viability of SNU-1 cells compared to untreated cells during 1, 2, 4, 6 or 24 h treatment periods.…"
-
39
-
40
Pairs of clusters that were significantly different from each other based on the layer profile of their cases.
منشور في 2024"…<p>Pairs of clusters that were significantly different from each other based on the layer profile of their cases.…"